The dopaminergic and sympathetic systems interact to regulate blood pressure. Our previous studies showed regulation of ␣1-adrenergic receptor function by D 1-like dopamine receptors in vascular smooth muscle cells. Because renalase could regulate circulating epinephrine levels and dopamine production in renal proximal tubules (RPTs), we tested the hypothesis that D 1-like receptors regulate renalase expression in kidney. (11, 24, 36, 45, 47) . There are interactions between dopamine receptors and the sympathetic nervous system (13, 30, 34, 35, 43) . Our previous studies found that, as an antihypertensive factor, activation of dopamine receptors, especially D 1 -like and D 3 receptors, inhibits the ␣ 1 -adrenergic receptor-mediated proliferation of vascular smooth muscle cells and relaxes the resistant artery preconstricted by norepinephrine (27). Moreover, stimulation of D 1 -like receptors inhibits the catecholamine production, partly via inhibition of tyrosine hydroxylase expression (18).
dopamine receptor; renalase; renal proximal tubule cells; renal proximal tubule cells; hypertension DOPAMINE, WELL KNOWN AS a neurotransmitter in the central nervous system, has been reported to be an important regulator of renal and adrenal function, sodium balance, and blood pressure and to be relevant to the pathogenesis and/or maintenance of hypertension (11, 24, 33, 36, 45, 47) . Dopamine receptors are classified into two families: the D 1 -like receptor subfamily includes the D 1 and the D 5 receptor, while the D 2 -like subfamily includes the D 2 , D 3 , and D 4 receptors. Whereas the D 1 -like receptors couple to the stimulatory G-protein G␣ S and thus activate adenylyl cyclase, all of the D 2 -like receptors couple to the inhibitory G-protein G␣ i /G␣ o and inhibit adenylyl cyclase and calcium channels and modulate potassium channels (11, 24, 36, 45, 47) .
There are interactions between dopamine receptors and the sympathetic nervous system (13, 30, 34, 35, 43) . Our previous studies found that, as an antihypertensive factor, activation of dopamine receptors, especially D 1 -like and D 3 receptors, inhibits the ␣ 1 -adrenergic receptor-mediated proliferation of vascular smooth muscle cells and relaxes the resistant artery preconstricted by norepinephrine (27) . Moreover, stimulation of D 1 -like receptors inhibits the catecholamine production, partly via inhibition of tyrosine hydroxylase expression (18) .
Renalase, a flavin adenine dinucleotide-dependent amine oxidase, plays an important role in the control of blood pressure by regulating sympathetic tone (5, 14, 15, 26, 40, 48) . It is known that renalase increases the degradation of epinephrine in the blood circulation (14, 15, 26, 40) . There is evidence showing renalase expression in renal proximal tubules (26, 40) . Renalase metabolizes circulating epinephrine and dihydroxyphenylanine, the latter is converted to dopamine by renal proximal tubules, the major source of renal dopamine (24, 45) . Because renalase could regulate circulating epinephrine levels and dopamine production in renal proximal tubules (RPTs), we tested the hypothesis that D 1 -like receptors regulate renalase expression and function in kidney. The effect of D 1 -like receptor on renalase expression was studied in immortalized RPT cells from Wistar-Kyoto (WKY) and spontaneously hypertensive rats (SHRs). Because the specific D 1 -like receptor involved in the regulation of dopamine release or metabolism is unknown, we also determined which D 1 -like receptor is involved in the process.
MATERIALS AND METHODS
WKY and SHRs. Male WKY and SHRs (SLRC Laboratory Animals, Shanghai, China), ranging in age from 9 to 16 wk, fed regular rat chow with normal sodium (0.4% NaCl) content, were used. Food but not water was withheld 24 h before the study. The rats were anesthetized with pentobarbital (50 mg/kg body wt ip) (21, 27) . Following a laparotomy, the kidneys were harvested, snap frozen in liquid nitrogen, and stored at Ϫ70°C. All studies were approved by the Daping Hospital Animal Care and Use Committee.
Cell culture. Immortalized RPT cells from WKY and SHRs (22, 42, 46) were cultured at 37°C in 95% air-5% CO2 atmosphere in FBS% DMEM/F-12 culture media, as previously described (41) . The cells (80% confluence) were extracted in ice-cold lysis buffer (PBS with 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 10
Ϫ3 mol/l EDTA, 10 Ϫ3 mol/l EGTA, 10
Ϫ3 mol/l PMSF, 10 g/ml aprotinin, and 10 g/ml leupeptin), sonicated, kept on ice for 1 h, and centrifuged at 16,000 g for 30 min. The supernatants were stored at Ϫ70°C until use for immunoblotting.
Immunoblotting. Uniform amounts of proteins, separated by SDSpolyacrylamide gel electrophoresis, were electrophoretically transferred onto nitrocellulose membranes. The membranes were blocked with 5% nonfat dry milk in Dulbecco's PBS with 0.05% Tween-20 and then probed with diluted affinity-purified goat polyclonal antibody to renalase (1:350; Sigma-Aldrich) (26, 40) , rabbit polyclonal antibody to D 1 receptor (1:200; Santa Cruz Biotechnology), D5 receptor (1:500; Santa Cruz Biotechnology), or ␤-actin antibody (1:600; Santa Cruz Biotechnology) overnight (19) . After being washed for five times (10 min each time), the membranes were incubated with diluted peroxidase-labeled goat anti-rabbit IgG or rabbit anti-goat IgG (Santa Cruz Biotechnology) in 5% milk for 1.5 h at room temperature. The signal was detected using chemiluminescence and developed on X-ray film. The density of the bands was quantified by densitometry using Quantiscan (Ferguson, MO), as previously reported (22, 42, 46) . The amount of protein transferred onto the membranes was verified by immunoblotting for ␤-actin.
Quantitative RT-PCR. Total RNA was isolated and quantified as described previously (22, 46) . For real-time quantitative RT-PCR (qRT-PCR) analysis, cDNA was synthesized from 0.5 mg of total RNA with a cDNA synthesis kit (High Capacity RNA-to-cDNA Kit; Takara, Tokyo, Japan). In the thermal cycle, 2 l cDNA were used per 25-l final reaction volume. PCRs were carried out with the Brilliant SYBR Green QPCR Master Mix kit (High Capacity RNA-to-cDNA Kit; Takara) in a total volume of 25 l. For renalase, the forward primer was 5=-TGCCAACAGTCCTCATAATCC-3= and the reverse primer was 5=-TCCTTCCTTCACTTCCATTCC-3= (GenBank Accession No. BC 005100). ␤-Actin served as a housekeeping/reference gene for normalization. For ␤-actin, the forward primer was 5=-AGTGTGACGTTGACATCCGT-3= and the reverse primer was 5=-GACTCATCGTACTCCTGCTT-3= (GenBank Accession No. BC 063166). The amplification profile for renalase and ␤-actin used on the BIO-RAD CFX96 (Bio-Rad Laboratories) was 95°C for 3 min followed by 40 cycles of 95°C per 10 s and 72°C per 30 s. qRT-PCR experiments were repeated for three times.
Antisense oligonucleotides. The effects of 50 nM of propyne/ phosphorothioate-modified antisense oligonucleotides for rat D 1 receptor, 5=-GGTAGAAGTGTTAGGAGCCAT-3= (GenBank Accession No. NC-005116) and D5 receptor, 5=-CAGCATGTCCGCT-GAGT-3= (GenBank Accession No. NC-005113) were compared with sense sequence controls D1 receptor, 5=-ATGGCTCCTAACACTTC-TACC-3= and D5 receptor, 5=-ACTCAGCGCGACATGCTG-3= (42, 44) . Briefly, cells were grown in six-well plates until 50% confluence, and 50 nM antisense or scrambled oligonucleotides were mixed with 6 l of oligofectamine in Optimem medium (Invitrogen Life Technologies) and incubated for 24 h and then switched to growth medium and incubated for an another 24 h. Fenoldopam (10 Ϫ6 mol/l) was then added to the medium without growth factors for 24 h, lysed, and processed for immunoblotting for renalase and D1 and D5 receptors (19, 49) .
To determine the specificity of renalase expression and activity measurements, we used renalase small interfering (si)RNA to inhibit the renalase expression. The antisense oligonucleotides for renalase was 3=-TdTCGGUCAUGUAGUGGUCAUU-5=, and the scramble oligonucleotides was 5=-GCCAGUACAUCACCAGUAAdTdT-3=.
Renalase activity. The kidneys and cells were harvested as above. The supernatants were used for assay of renalase activity, as reported previously (38) . Renalase, as a FAD-dependent oxidoreductase, uses NADH as a cofactor to reduce FAD (14, 15, 26, 38, 40) . Therefore, the amount of NADH oxidized to NAD ϩ (NADH oxidation) is considered to indicate renalase activity (14, 15, 26, 38, 40) . min. The amount of NADH oxidized to NAD ϩ was calculated from the decrease in absorbance at 340 nm using a molar extinction coefficient of 0.00622 l·M Ϫ1 ·cm Ϫ1 . The background, i.e., changes in absorbance obtained with BSA, was subtracted from all the readings (16, 38) .
Statistical analysis. In the our study, the data are expressed as means Ϯ SE. Statistical analyses were performed by one-way ANOVA followed by Holm-Sidak's post hoc multiple comparison test (for comparison of more than 2 groups) or Student's t-test (for comparison of 2 groups). A value of P Ͻ 0.05 was considered significant. mol/l) for 48 h, renalase expression in WKY RPT cells was suppressed ϳ72.39% (Fig. 1) .
RESULTS

D 1 -like receptors increase renalase expression in WKY RPT cells but decrease it in SHR RPT
Stimulation of D 1 -like receptors with fenoldopam increased renalase expression in a concentration-and time-dependent manner in WKY RPT cells (Fig. 2, A and B) . The stimulatory effect was evident at 10 Ϫ6 mol/l with a 49.5% increase in renalase expression. In contrast, in RPT cells from SHR, fenoldopam treatment decreased renalase expression (Figs. 2,  C and D) . The basal level of renalase expression was also higher in WKY than SHR cells (Fig. 2E) .
The specificity of fenoldopam as a D 1 -like receptors agonist was determined by studying the effect of the D 1 -like receptor antagonist SCH23390 (24, 27, 44) . Consistent with the results shown in Fig. 2 , A and C, fenoldopam (10 Ϫ6 mol/l for 24 h) increased renalase expression in RPT cells from WKY cells and decreased renalase expression in SHR cells. The D 1 -like receptor antagonist SCH23390 (10 Ϫ6 mol/l), by itself, had no effect on renalase expression in both WKY and SHR cells but reversed the stimulatory effect of fenoldopam on renalase expression in WKY cells and inhibitory effect in SHR cells (Fig. 2, F and G) .
Renalase has intrinsic NADH oxidase activity (14 -16, 38) . Treatment of RPT cells with varying concentrations of fenoldopam (10 Ϫ7 -10 Ϫ5 mol/l) for 24 h caused a concentration-dependent increase in NADH oxidation in WKY cells and WKY cell culture medium and a concentration-dependent decrease in NADH oxidation in SHR cells and SHR cell culture medium (Fig. 3, A and B) .
To determine the mechanisms involved in the differential regulation of D 1 -like receptor on renalase expression in RPT cells from WKY and SHRs, qRT-PCR was used to study the effect of fenoldopam on renalase transcription. We found that fenoldopam increased renalase transcription in WKY RPT cells in a concentration-dependent manner (Fig. 4A) but had no significant effect in SHR cells (Fig. 4B) .
To study potential posttranscriptional mechanisms of renalase regulated by D 1 -like receptors, we examined protein expression in the presence of 10 g/ml cycloheximide (CHX) to inhibit de novo protein synthesis (10); steady-state levels of renalase were determined by immunoblotting (Fig. 5, A and B) .
Ϫ6 mol/l) accelerated the degradation of renalase protein in SHR cells (Fig. 5B) but not in WKY rat cells (Fig. 5A) . Consistent with Fig. 2 , B and D, there was no effect of vehicle or fenoldopam on renalase expression for up to 4 -5 h without CHX treatment (Fig. 5, C and D) .
To determine whether or not the regulation of D 1 -like receptor on renalase has physiological relevance, we measured renalase expression in the kidneys from WKY and SHRs. We found that renalase expression was lower in kidneys from SHRs than those from WKY rats [ratio of renalase to ␤-actin: (9, 44) , by itself, had no effect on renalase expression but blocked the stimulatory effect of fenoldopam on renalase expression in RPT cells (Fig. 6A) , indicating that PKC was involved in the stimulatory action of fenoldopam. To confirm this finding, we also evaluated the effect of PKC activator (PMA) (25, 28) on renalase expression in RPT cells.
PMA increased renalase expression in a concentration-dependent way in WKY RPY cells (Fig. 6B) . A PKA inhibitor (PKA inhibitor 14 -22, 10 Ϫ6 mol/l) (4) and a calcium channel blocker (nicardipine, 10 Ϫ6 mol/l) (23) had no effect on the stimulatory effect of fenoldopam on renalase expression in WKY RPT cells (data not shown).
Role of D 5 (Fig. 7, A and B) . (Fig. 7, C and D) .
DISCUSSION
There are several novel observations in our study. We showed that the D 1 -like receptor agonist fenoldopam increased As indicated in the Introduction, there are interactions between dopamine and adrenergic receptors outside neural cells (13, 27, 30, (33) (34) (35) 43) . For example, activation of D 1 -like receptors induces relaxation of resistance arteries preconstricted by norepinephrine (27, 33) . Moreover, D 1 -like receptors inhibit the ␣ 1 -adrenergic receptor-mediated proliferation of vascular smooth muscle cells (27) . Norepinephrine increases oxidative stress, which is inhibited in the presence of a dopamine-receptor agonist (36, 45, 47) . In addition to dopamineand adrenergic-receptor interaction, activation of dopamine receptors, including D 1 -like receptors, inhibits the catecholamine production (12, 13, 18, 30, 35) . Damase-Michel and colleagues (13, 35) showed that infusion of the D 1 -like receptor agonist fenoldopam reduces plasma norepinephrine levels in conscious sinoaotic denervated dogs. Ferrari et al. (18) found that the D 1 -like receptor-mediated decrease of catecholamine production is mainly via inhibition of tyrosine hydroxylase expression in human lymphocytes.
Ten to fifteen percent of catecholamines in the renal peritubular blood are metabolized (1) . As an important amino oxidase, activation of renalase increases the degradation of epinephrine and dihydroxyphenylanine in the circulation (14, 15, 26, 40) . Dihydroxyphenylanine taken up by renal proximal tubules is the major source or renal dopamine production (7). Renalase is abundantly expressed in RPTs (26, 40) , but whether or not dopamine receptor has an effect on renalase expression and therefore on epinephrine levels is not clear. Dopamine may negatively interact with the sympathetic nervous system, including epinephrine (45) . Our present study shows that activation of D 1 -like receptor increases renalase expression in RPT cells from WKY rats, indicating that in addition to an inhibitory effect of fenoldopam on tyrosine hydroxylase activity, the regulation of fenoldopam on renalase expression and activity could be involved in the regulation of epinephrine catabolism in kidney.
The D 1 -like receptor family is comprised of D 1 and D 5 receptors. Activation of the D 1 or D 5 receptor increases adenylyl cyclase activity (11, 24, 33, 36, 45, 47) . However, the effect of D 1 or D 5 receptor is not always the same, for example, the D 5 receptor, not the D 1 receptor, is responsible for the degradation of AT 1 receptors in RPT cells (19) . In the kidney the D 5 receptor, but not the D 1 receptor, is linked to G␣ 12 and G␣ 13 . Stimulation of the D 5 receptor increases the association between the D 5 receptor and G␣ 12 or G␣ 13 and may impair the stimulatory effect of G␣ 12 /G␣ 13 on sodium hydrogen exchanger 3 activity (49) . Previous studies have shown that the D 5 receptor may be important in the regulation of catecholamine release and plasma concentration. Dahmer and Senogles (12) Ϫ6 mol/l) for 24 h. Results are expressed as the ratio of renalase to ␤-actin densities (n ϭ 6; *P Ͻ 0.05 vs. control).
sion (5, 14, 15, 26, 40, 48) . We found that activation of the D 1 -like receptor increases renalase expression in WKY cells but decreases it in SHRs. The stimulatory effect of the D 1 -like receptor on renalase expression could be explained by an increase renalase transcription because fenoldopam increases renalase mRNA expression in WKY rats. The inhibitory effect of fenoldopam on renalase expression in SHR cells is not due to a decrease in renalase transcription but could be ascribed to the augmented renalase degradation. These in vitro findings have relevance in vivo because renalase expression and activity are lower in kidneys from SHRs than WKY rats. Because renalase increases the degradation of epinephrine, the decreased expression and activity of renalase would lead to increased epinephrine concentration in kidney in SHRs, which would increase sodium transport and vascular smooth muscle contractility (6, 45) . However, the increased degradation of dihydroxyphenylanine by renalase could also decrease the production of dopamine (24) . Therefore, studying the regulation of renalase expression and activity in kidney is important. Our present study found that stimulation of D 1 -like receptor with fenoldopam increases renalase expression in WKY cells but not in SHR cells. We have reported that the renal D 1 -like receptor function is impaired in SHRs due to the hyperphosphorylation of the D 1 receptor (17, 31) , which has been ascribed to increased constitutive activity of G protein-coupled receptor kinase 4 (GRK4) (17, 31) . Whether or not this strategy is helpful in increasing renalase expression and activity in kidney of SHRs needs to be confirmed in the future.
In summary, we have demonstrated that the D 1 -like receptor, via the D 5 receptor, increases renalase expression in RPT cells from WKY rats but, in contrast, decreases it in SHR cells. The stimulatory effect of the D 5 receptor on renalase expression is ascribed to increased renalase transcription in WKY cells, while the inhibitory effect of the D 1 -like receptor on renalase expression in SHR cells may be due to augmented degradation.
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